Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Inclusion Criteria: * Subject is ≥ 18 years at the time of signing informed consent; * Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies; * Presence of measurable or evaluable disease; * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2; * Contraceptives or other approved avoidance of pregnancy measures Exclusion Criteria: * Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression; * Concomitantly taking anti-cancer therapy (bisphosphonates are permitted); * Undergone major surgery ≤ 2 weeks prior to starting study drug; * Evidence of mucosal or internal bleeding; * Impaired cardiac function or conduction defect; * Concurrent severe and/or uncontrolled medical conditions